​

Abbott Laboratories (ABT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABT Stock Forecast

Abbott Laboratories (ABT) stock forecast, based on 43 Wall Street analysts, predicts a 12-month average price target of $121.82, with a high of $130.00 and a low of $112.00. This represents a 18.84% increase from the last price of $102.51.

$80 $90 $100 $110 $120 $130 High: $130 Avg: $121.82 Low: $112 Last Closed Price: $102.51

ABT Stock Rating

Abbott Laboratories stock's rating consensus is Buy, based on 43 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 34 Buy (79.07%), 9 Hold (20.93%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 43 0 9 34 Strong Sell Sell Hold Buy Strong Buy

ABT Price Target Upside V Benchmarks

TypeNameUpside
StockAbbott Laboratories18.84%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks19.68%

Price Target Trends

1M3M12M
# Anlaysts7935
Avg Price Target$122.00$123.22$130.00
Last Closing Price$102.51$102.51$102.51
Upside/Downside19.01%20.20%26.82%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 264185--27
Sep, 264176--27
Aug, 264167--27
Jul, 264177--28
Jun, 264176--27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 23, 2026UBS$120.00$103.0816.41%17.06%
Oct 23, 2026Wells Fargo$120.00$102.5117.06%17.06%
Oct 22, 2026Marie ThibaultBTIG$125.00$100.5724.29%21.94%
Oct 22, 2026Wells Fargo$119.00$100.5718.33%16.09%
Oct 22, 2026Robert W. Baird$123.00$100.5722.30%19.99%
Oct 16, 2026New Street$120.00$104.6014.72%17.06%
Oct 06, 2026Barclays$120.00$98.1722.24%17.06%
Oct 02, 2026Ed Ridley-DayRedburn Partners$127.00$96.7131.32%23.89%
Aug 13, 2026Wolfe Research$130.00$110.9217.20%26.82%
Jul 28, 2026Patrick WoodUBS$125.00$108.8414.85%21.94%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2026Evercore ISIOutperformOutperformhold
Oct 22, 2026BTIGBuyBuyhold
Oct 22, 2026Wells FargoOverweightOverweighthold
Oct 19, 2026UBSBuyBuyhold
Oct 16, 2026Cowen & Co.BuyBuyhold
Oct 06, 2026BarclaysOverweightOverweightinitialise
Aug 21, 2026Cowen & Co.BuyBuyhold
Aug 13, 2026CitigroupBuyBuyhold
Aug 13, 2026Wolfe ResearchOutperformOutperformupgrade
Jul 28, 2026UBSBuyBuyhold

Financial Forecast

EPS Forecast

$3 $4 $5 $6 $7 $8 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$3.97$3.94$3.30$7.67$3.74----
Avg Forecast$5.10$5.23$4.44$4.67$5.16$5.70$6.30$6.92$7.60
High Forecast$5.15$5.29$4.45$4.68$5.21$6.13$6.99$7.14$7.84
Low Forecast$5.05$5.16$4.43$4.66$5.08$5.49$5.55$6.82$7.49
Surprise %-22.16%-24.67%-25.68%64.24%-27.52%----

Revenue Forecast

$35B $40B $45B $50B $55B $60B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$43.08B$43.65B$40.11B$41.95B$44.33B----
Avg Forecast$42.32B$43.22B$40.08B$42.00B$44.38B$47.66B$51.09B$54.53B$58.49B
High Forecast$42.66B$43.58B$40.26B$42.08B$45.00B$48.69B$51.13B$55.85B$59.91B
Low Forecast$41.99B$42.75B$39.95B$41.87B$44.24B$47.22B$51.04B$53.94B$57.86B
Surprise %1.79%0.99%0.08%-0.12%-0.12%----

Net Income Forecast

$5B $6B $8B $10B $12B $14B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$7.07B$6.93B$5.72B$13.40B$6.52B----
Avg Forecast$5.75B$6.73B$5.70B$8.18B$8.99B$10.17B$10.96B$12.10B$13.29B
High Forecast$6.90B$8.07B$6.84B$8.19B$9.10B$10.72B$12.22B$12.48B$13.71B
Low Forecast$4.60B$5.38B$4.56B$8.16B$8.88B$9.61B$9.71B$11.93B$13.11B
Surprise %23.04%3.03%0.39%63.92%-27.44%----

ABT Forecast FAQ

Is Abbott Laboratories stock a buy?

Abbott Laboratories stock has a consensus rating of Buy, based on 43 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 34 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Abbott Laboratories is a favorable investment for most analysts.

What is Abbott Laboratories's price target?

Abbott Laboratories's price target, set by 43 Wall Street analysts, averages $121.82 over the next 12 months. The price target range spans from $112 at the low end to $130 at the high end, suggesting a potential 18.84% change from the previous closing price of $102.51.

How does Abbott Laboratories stock forecast compare to its benchmarks?

Abbott Laboratories's stock forecast shows a 18.84% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical device stocks industry (19.68%).

What is the breakdown of analyst ratings for Abbott Laboratories over the past three months?

  • October 2026: 14.81% Strong Buy, 66.67% Buy, 18.52% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 14.81% Strong Buy, 62.96% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 14.81% Strong Buy, 59.26% Buy, 25.93% Hold, 0% Sell, 0% Strong Sell.

What is Abbott Laboratories’s EPS forecast?

Abbott Laboratories's average annual EPS forecast for its fiscal year ending in December 2026 is $5.7, marking a 52.41% increase from the reported $3.74 in 2025. Estimates for the following years are $6.3 in 2027, $6.92 in 2028, and $7.6 in 2029.

What is Abbott Laboratories’s revenue forecast?

Abbott Laboratories's average annual revenue forecast for its fiscal year ending in December 2026 is $47.66B, reflecting a 7.51% increase from the reported $44.33B in 2025. The forecast for 2027 is $51.09B, followed by $54.53B for 2028, and $58.49B for 2029.

What is Abbott Laboratories’s net income forecast?

Abbott Laboratories's net income forecast for the fiscal year ending in December 2026 stands at $10.17B, representing an 55.82% increase from the reported $6.52B in 2025. Projections indicate $10.96B in 2027, $12.1B in 2028, and $13.29B in 2029.